Alzheimer DiseaseLatAmFINGERSNCT06492967
LatAm-FINGERS Initiative for Cognitive Change
A study testing Systematic Lifestyle Intervention and Flexible Lifestyle Intervention in people with Alzheimer Disease, run by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia at 13 sites in 12 countries.
Trial summary
Currently, 40% of global dementia cases can be prevented through lifestyle changes, with Latin America having a 56% potential reduction due to its high-risk factors. At the moment, there are no medications that halt the clinical expression of dementia. Read more about this study
- Who is it for?
- Ages 60 to 77 years
- Conditions the study is for
- Alzheimer Disease
- What is being tested?
- Systematic Lifestyle Intervention and Flexible Lifestyle Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,065 participants
- Where
- 13 sitesin 12 countries
- Study dates
- 27 Oct 2021to 7 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 77 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age: 60-77 years.
- Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score > 6.
- Mini-Mental State Examination (MMSE) z score between 0 and -1.5 OR
- CERAD Word List Learning Task (10 word x 3 repetitions) < 0 z score OR
- CERAD (delayed word list recall) < z score < 0
Who cannot join
- MMSE < 20
- Dementia
- Any medical condition that affects the participant's safety.
- Severe osteoarticular problems that preclude the implementation of the physical activity intervention outlined in the protocol, such as, for example: osteoarthrosis of the knee(s), coxofemoral, or other.
- Significant neurological disease, including dementia, cognitive impairment, Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis or history of significant head injury with persistent neurological sequelae or structural brain abnormalities, major depressive disorder within the last 2 months, history of bipolar disorder or schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders V (DSM V) criteria.
- Severe cardiovascular disease, including heart failure, clinically significant aortic stenosis, history of uncontrolled acute myocardial infarction (AMI) or angina and Cardiac rhythm disorders: g3 conduction block, uncontrolled arrhythmia, alterations in Q wave, S waver and T wave segment or QT segment and auricular fibrillation (AF) of less than one year of evolution, venous thrombosis or pulmonary thromboembolism (PTE) of less than 6 months of evolution and any pathology that in clinical judgment compromises the intervention of physical activity.
Show all 22Show fewer
- Body Mass Index >40
- Cerebral vascular disease in the last 2 years.
- Insulin-dependent diabetes mellitus.
- Pulmonary disease requiring oxygen and/or steroids.
- Renal disease defined as increased renal glomerular filtration rate <60ml/min/1.73mt2 or albumin excretion rate (AER) > 30mg/24 hrs.
- Clinically significant laboratory abnormalities as judged by the investigator.
- History within the last 2 years of treatment for primary or recurrent malignant disease.
- History of hip fracture, knee replacement, or spinal surgery within the last 6 months.
- Being in cardiopulmonary rehabilitation.
- History of bariatric surgery.
- Cardiac surgery in the last year.
- Severe sensory loss or loss of communication skills.
- No schooling.
- Use of psychoactive medications within the past 3 months, including tricyclic antidepressants, antipsychotics, psychotropic mood-stabilizing agents (e.g., lithium salts), psychostimulants, opioid analgesics, antiparkinsonian medications, anticonvulsant medications (except gabapentin and pregabalin for non-convulsant indications), systemic corticosteroids, or medications with significant central anticholinergic activity; in the absence of major depression, stable doses of selective serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors are permitted.
- Active participation in another intervention study.
- History of alcoholism or substance abuse in the last 2 years, according to DSM V criteria.
Trial locations and contacts
13 sites in 12 countries.
13 sites in 12 countries
Brazil2 sites
Universidade Federal de Minas Gerais
Belo Horizonte, Minas Gerais
University of Sao Paulo School of Medicine
São Paulo
Dominican Republic1 site
Universidad Nacional Pedro Henriquez Urena (UNPHU)
Santo Domingo
Mexico1 site
Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez
Mexico City
About this study
Official title: Latin American Lifestyle Intervention Initiative to Reduce the Risk and Prevent Cognitive Impairment.
Currently, 40% of global dementia cases can be prevented through lifestyle changes, with Latin America having a 56% potential reduction due to its high-risk factors. At the moment, there are no medications that halt the clinical expression of dementia.
LatAm-FINGERS, a multicenter study across 12 Latin American countries, aims to study the feasibility of an intervention modifying lifestyle in individuals aged 60 to 77 at risk of dementia. Success could influence public policy on clinical care for older adults.
Read the detailed description
Today we know that 40% of dementia cases worldwide can be prevented through lifestyle modification. If we look at Latin America, this number is 56%. Latin America is a region with high-risk factors for dementia due to weakened socioeconomic infrastructure, an impoverished healthcare system, and low average education levels in the region. Additionally, we know that cardiovascular health is an important factor in the development of dementia.
Under this scenario, LatAm-FINGERS is a multicenter study designed to prevent memory decline through lifestyle modification in people aged 60 to 77 at risk of dementia. Twelve Latin American countries are participating (Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Mexico, Puerto Rico, Uruguay, Costa Rica, Ecuador, and Peru), with 100 individuals per center. These individuals are randomly assigned to two groups: (1) a group making systematic lifestyle changes (physical and cognitive training, implementation of the Mediterranean-dietary approach to stop hypertension (DASH) Intervention for Neurodegenerative Delay (MIND) diet, socialization, and regular health check-ups) and (2) a group receiving regular health advice.
The main objective of LatAm-FINGERS is to determine if this intervention is feasible in Latin America. Secondarily, we want to test if this lifestyle change can lead to improvements in participants' cognition over time (2 years).
If successful, the results of this study will have large-scale implications for public policy regarding the standard of clinical care and prescriptive practices for a fast-growing and vulnerable population of older adults.
LatAm-FINGERS is based on the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), which demonstrated that lifestyle modification promotes positive changes in memory and attention. Additionally, our study is aligned with the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER), which is conducting a similar intervention in the United States.
This project is fully funded by the Alzheimer's Association.
- Conditions
- Alzheimer Disease
- Being tested
- Systematic Lifestyle Intervention, Flexible Lifestyle Intervention
- Keywords
- Alzheimer's Disease, Brain Diseases, Lifestyle
- Medical subject headings
- Alzheimer Disease, Brain Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Systematic Lifestyle InterventionBehavioural
Also called Systematic Lifestyle Intervention (SLI)
Lifestyle intervention that involves providing participants with education, support, and tangible tools to assist them in developing and carrying out healthier lifestyle practices.
Flexible Lifestyle InterventionBehavioural
Also called Flexible Lifestyle Intervention (FLI)
Lifestyle intervention that involves a structured program of diet, physical and cognitive exercise, and management of cardiometabolic risks.
| Study group | Role | What they receive |
|---|---|---|
| Systematic Lifestyle Intervention | Experimental | Lifestyle modification program that involves participants completing structured activities that target diet, physical exercise, and intellectual and social stimulation. Receives: Behavioral: Systematic Lifestyle Intervention |
| Flexible Lifestyle Intervention | Experimental | Lifestyle modification program that is developed by the participant to meet his/her specific needs. Receives: Behavioral: Flexible Lifestyle Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reach
It refers to the effectiveness of recruiting the target population. It will be measured by the ratio of randomized participants versus the ratio of screen-failures.
Measured: Up to 2 years
Implementation
Adherence rate of participants to the protocol in both arms. It will be measured through the percentage of attendance to group meetings, attendance to physical and cognitive training sessions, and completion of dietary records.
Measured: Up to 2 years
Maintenance
It consists of each center's ability to sustain the intervention. It will be measured through the percentage of subjects who complete outcome measures at each trial event (baseline, 6, 12, 18, and 24 months).
Measured: Up to 2 years
Secondary outcomes (1)
Global cognition
Global cognitive function will be obtained from a composite score derived from subtest scores on the LatAm Neuropsychological Test Battery (LatAm-NTB) that includes: Free and Cued Selective Reminding Test, Logical Memory, Digit Span, Concept Shifting Test, Digit Symbol Substitution Test, Semantic and phonological fluency, Trial Making Test, Stroop Test.
Scores from each individual test will be converted to z-scores that typically range from -3 to 3, with higher scores reflecting better performance, and averaged to form a composite.
Measured: Up to 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2024
- Study start27 Oct 2021
- Primary completion7 Nov 2025
- Study completion7 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Alzheimer DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Multicenter study with blind evaluators, evaluating the feasibility of a lifestyle intervention over two years.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 1,065 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
- Sponsor type
- University, hospital or other
- Collaborators
- Alzheimer's Association
- Responsible party
- Principal investigator, Lucia Crivelli, Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
- Investigators
- Ricardo Francisco Allegri, MD, Ph.D, Principal investigator, Fleni Neurological Institute, Buenos Aires, ArgentinaLucía Crivelli, Ph.D, Principal investigator, Fleni Neurological Institute, Buenos Aires, ArgentinaGustavo Emilio Sevlever, MD, Ph.D, Principal investigator, Fleni Neurological Institute, Buenos Aires, ArgentinaMaría Isabel Cusicanqui, MD, Principal investigator, Centro Neurológico Mente Activa, La Paz, BoliviaRicardo Nitrini, MD, Ph.D, Principal investigator, University of São Paulo School of Medicine, São Paulo, BrazilPaulo Caramelli, MD, Ph.D, Principal investigator, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilCarolina Delgado Derio, MD, MSc, Principal investigator, Hospital Clínico Universidad de Chile, Santiago, ChileFrancisco Lopera, MD, Ph.D, Principal investigator, Antioquia University, Colombia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06492967
- Sponsor's protocol ID
- SG-21-715176-LatAm-FINGERS
- Acronym
- LatAmFINGERS
- Status last verified
- Apr 2026
- First submitted
- 30 May 2023
- Last updated
- 4 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Crivelli L, Calandri IL, Suemoto CK, Salinas RM, Velilla LM, Yassuda MS, Caramelli P, Lopera F, Nitrini R, Sevlever GE, Sosa AL, Acosta D, Baietti AMC, Cusicanqui MI, Custodio N, De Simone SD, Derio CD, Duque-Penailillo L, Duran JC, Jimenez-Velazquez IZ, Leon-Salas JM, Bergamo Y, Clarens MF, Damian A, Demey I, Helou MB, Marquez C, Martin ME, Martin MDGM, Querze D, Surace EI, Acosta-Egea S, Aguirre-Salvador E, de Souza LC, Cancado GHDCP, Brucki SMD, Friedlaender CV, Gomes KB, Gutierrez M, Rios CL, Galindo JGM, Montesinos R, Nunez-Herrera A, Ospina-Henao S, Rodriguez G, Masson VR, Sanchez M, Schenk CE, Soto L, Barbosa MT, Tosatti JAG, Vicuna Y, Espeland M, Hakansson K, Kivipelto M, Baker L, Snyder H, Carrillo M, Allegri RF. Latin American Initiative for Lifestyle Intervention to Prevent Cognitive Decline (LatAm-FINGERS): Study design and harmonization. Alzheimers Dement. 2023 Sep;19(9):4046-4060. doi: 10.1002/alz.13101. Epub 2023 May 19.
PubMed 37204054Crivelli L, Suemoto CK, Sosa AL, Lopera F, Aguillon D, Allegri RF, Nitrini R, Calandri IL, Velilla-Jimenez L, Yassuda MS, Acosta-Baena N, Salinas RM, Charamelo A, Derio CD, Acosta DM, Leon-Salas JM, Duque-Penailillo L, Cusicanqui MI, Custodio N, Anchia-Alfaro A, Nunez-Herrera A, Rubens A, Leites A, Vigil-Martinez A, Damian A, Flores-Blanco BM, Custodio B, Laforcada C, Marquez C, Friedlaender CV, Espinoza-Cruz CG, Canadas C, Peixoto C, Munoz DH, Slezak DF, Felix E, Aguirre-Salvador E, Surace EI, Mariani F, De La Torre GR, Verastegui G, Keller G, Peixoto GH, Morilla HA, Jimenez-Velazquez IZ, More JY, Rodriguez JF, Tosatti JAG, de Faria Rocha JV, Saldarriaga-Hernandez J, Huilca JC, Garcia-Molina JT, Martinez-Galindo JG, Duran JC, Rodriguez JG, Gomes KB, Cesar-Freitas KG, Aguero K, Mora-Villalobos L, Asprilla LO, de Souza LC, Soto L, Cortabarria L, Baldeon L, Carreira LL, Marin-Buitrago L, Moreno MC, Barbosa MT, Torheim M, Magalhaes MAZ, da Graca Morais Martin M, Martin ME, Torres MF, Menendez M, Hernandez MA, Granizo MS, Gutierrez M, Corvalan N, Mora PJ, Peguero P, Ramirez-Santos R, Fernandez RS, Montesinos R, Ospina-Henao S, Montes SY, Santero S, Brucki SMD, Josephy-Hernandez S, Vazquez TC, Bergamo Y, Bocanegra Y, Munoz YA, Vicuna Y, Lora ZDC, Kivipelto M, Raman R, Espeland MA, Baker LD, Snyder HM, Sevlever GE, Carrillo MC, Caramelli P; LatAm-FINGERS Study Group. Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial. Lancet. 2026 Aug 1;408(10553):417-429. doi: 10.1016/S0140-6736(26)01278-X. Epub 2026 Jul 13.
PubMed 42442374
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Latin American Lifestyle Intervention Initiative to Reduce the Risk and Prevent Cognitive Impairment.
- ClinicalTrials.gov ID
- NCT06492967
- Acronym / sponsor ID
- LatAmFINGERS / SG-21-715176-LatAm-FINGERS
- Conditions
- Alzheimer Disease
- Keywords
- Alzheimer's Disease, Brain Diseases, Lifestyle
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,065 participants (actual)
- Lead sponsor
- Fundación para la Lucha contra las Enfermedades Neurológicas de la InfanciaUniversity, hospital or other
- Collaborators
- Alzheimer's Association
- Study start
- 27 Oct 2021 (actual)
- Primary completion
- 7 Nov 2025 (actual)
- Study completion
- 7 Nov 2025 (actual)
- First posted
- 9 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Currently, 40% of global dementia cases can be prevented through lifestyle changes, with Latin America having a 56% potential reduction due to its high-risk factors. At the moment, there are no medications that halt the clinical expression of dementia.
LatAm-FINGERS, a multicenter study across 12 Latin American countries, aims to study the feasibility of an intervention modifying lifestyle in individuals aged 60 to 77 at risk of dementia. Success could influence public policy on clinical care for older adults.
Detailed description
Today we know that 40% of dementia cases worldwide can be prevented through lifestyle modification. If we look at Latin America, this number is 56%. Latin America is a region with high-risk factors for dementia due to weakened socioeconomic infrastructure, an impoverished healthcare system, and low average education levels in the region. Additionally, we know that cardiovascular health is an important factor in the development of dementia.
Under this scenario, LatAm-FINGERS is a multicenter study designed to prevent memory decline through lifestyle modification in people aged 60 to 77 at risk of dementia. Twelve Latin American countries are participating (Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Mexico, Puerto Rico, Uruguay, Costa Rica, Ecuador, and Peru), with 100 individuals per center. These individuals are randomly assigned to two groups: (1) a group making systematic lifestyle changes (physical and cognitive training, implementation of the Mediterranean-dietary approach to stop hypertension (DASH) Intervention for Neurodegenerative Delay (MIND) diet, socialization, and regular health check-ups) and (2) a group receiving regular health advice.
The main objective of LatAm-FINGERS is to determine if this intervention is feasible in Latin America. Secondarily, we want to test if this lifestyle change can lead to improvements in participants' cognition over time (2 years).
If successful, the results of this study will have large-scale implications for public policy regarding the standard of clinical care and prescriptive practices for a fast-growing and vulnerable population of older adults.
LatAm-FINGERS is based on the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), which demonstrated that lifestyle modification promotes positive changes in memory and attention. Additionally, our study is aligned with the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER), which is conducting a similar intervention in the United States.
This project is fully funded by the Alzheimer's Association.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Multicenter study with blind evaluators, evaluating the feasibility of a lifestyle intervention over two years.
| Arm | Type | Receives |
|---|---|---|
| Systematic Lifestyle Intervention | Experimental | Behavioral: Systematic Lifestyle InterventionLifestyle modification program that involves participants completing structured activities that target diet, physical exercise, and intellectual and social stimulation. |
| Flexible Lifestyle Intervention | Experimental | Behavioral: Flexible Lifestyle InterventionLifestyle modification program that is developed by the participant to meet his/her specific needs. |
Who may qualify
- Ages
- 60 to 77 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age: 60-77 years.
- Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score > 6.
- Mini-Mental State Examination (MMSE) z score between 0 and -1.5 OR
- CERAD Word List Learning Task (10 word x 3 repetitions) < 0 z score OR
- CERAD (delayed word list recall) < z score < 0
Key exclusion criteria (22 listed)
- MMSE < 20
- Dementia
- Any medical condition that affects the participant's safety.
- Severe osteoarticular problems that preclude the implementation of the physical activity intervention outlined in the protocol, such as, for example: osteoarthrosis of the knee(s), coxofemoral, or other.
- Significant neurological disease, including dementia, cognitive impairment, Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis or history of significant head injury with persistent neurological sequelae or structural brain abnormalities, major depressive disorder within the last 2 months, history of bipolar disorder or schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders V (DSM V) criteria.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Systematic Lifestyle InterventionAlso: Systematic Lifestyle Intervention (SLI)Lifestyle intervention that involves providing participants with education, support, and tangible tools to assist them in developing and carrying out healthier lifestyle practices. | Behavioural | Systematic Lifestyle Intervention |
| Flexible Lifestyle InterventionAlso: Flexible Lifestyle Intervention (FLI)Lifestyle intervention that involves a structured program of diet, physical and cognitive exercise, and management of cardiometabolic risks. | Behavioural | Flexible Lifestyle Intervention |
Primary outcome
Reach
Time frame: Up to 2 years
It refers to the effectiveness of recruiting the target population. It will be measured by the ratio of randomized participants versus the ratio of screen-failures.
Implementation
Time frame: Up to 2 years
Adherence rate of participants to the protocol in both arms. It will be measured through the percentage of attendance to group meetings, attendance to physical and cognitive training sessions, and completion of dietary records.
Maintenance
Time frame: Up to 2 years
It consists of each center's ability to sustain the intervention. It will be measured through the percentage of subjects who complete outcome measures at each trial event (baseline, 6, 12, 18, and 24 months).
1 secondary outcome
Global cognition
Time frame: Up to 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2026.
- Background: PubMed 37204054Crivelli L, Calandri IL, Suemoto CK, Salinas RM, Velilla LM, Yassuda MS, Caramelli P, Lopera F, Nitrini R, Sevlever GE, Sosa AL, Acosta D, Baietti AMC, Cusicanqui MI, Custodio N, De Simone SD, Derio CD, Duque-Penailillo L, Duran JC, Jimenez-Velazquez IZ, Leon-Salas JM, Bergamo Y, Clarens MF, Damian A, Demey I, Helou MB, Marquez C, Martin ME, Martin MDGM, Querze D, Surace EI, Acosta-Egea S, Aguirre-Salvador E, de Souza LC, Cancado GHDCP, Brucki SMD, Friedlaender CV, Gomes KB, Gutierrez M, Rios CL, Galindo JGM, Montesinos R, Nunez-Herrera A, Ospina-Henao S, Rodriguez G, Masson VR, Sanchez M, Schenk CE, Soto L, Barbosa MT, Tosatti JAG, Vicuna Y, Espeland M, Hakansson K, Kivipelto M, Baker L, Snyder H, Carrillo M, Allegri RF. Latin American Initiative for Lifestyle Intervention to Prevent Cognitive Decline (LatAm-FINGERS): Study design and harmonization. Alzheimers Dement. 2023 Sep;19(9):4046-4060. doi: 10.1002/alz.13101. Epub 2023 May 19.
- Derived from this study: PubMed 42442374Crivelli L, Suemoto CK, Sosa AL, Lopera F, Aguillon D, Allegri RF, Nitrini R, Calandri IL, Velilla-Jimenez L, Yassuda MS, Acosta-Baena N, Salinas RM, Charamelo A, Derio CD, Acosta DM, Leon-Salas JM, Duque-Penailillo L, Cusicanqui MI, Custodio N, Anchia-Alfaro A, Nunez-Herrera A, Rubens A, Leites A, Vigil-Martinez A, Damian A, Flores-Blanco BM, Custodio B, Laforcada C, Marquez C, Friedlaender CV, Espinoza-Cruz CG, Canadas C, Peixoto C, Munoz DH, Slezak DF, Felix E, Aguirre-Salvador E, Surace EI, Mariani F, De La Torre GR, Verastegui G, Keller G, Peixoto GH, Morilla HA, Jimenez-Velazquez IZ, More JY, Rodriguez JF, Tosatti JAG, de Faria Rocha JV, Saldarriaga-Hernandez J, Huilca JC, Garcia-Molina JT, Martinez-Galindo JG, Duran JC, Rodriguez JG, Gomes KB, Cesar-Freitas KG, Aguero K, Mora-Villalobos L, Asprilla LO, de Souza LC, Soto L, Cortabarria L, Baldeon L, Carreira LL, Marin-Buitrago L, Moreno MC, Barbosa MT, Torheim M, Magalhaes MAZ, da Graca Morais Martin M, Martin ME, Torres MF, Menendez M, Hernandez MA, Granizo MS, Gutierrez M, Corvalan N, Mora PJ, Peguero P, Ramirez-Santos R, Fernandez RS, Montesinos R, Ospina-Henao S, Montes SY, Santero S, Brucki SMD, Josephy-Hernandez S, Vazquez TC, Bergamo Y, Bocanegra Y, Munoz YA, Vicuna Y, Lora ZDC, Kivipelto M, Raman R, Espeland MA, Baker LD, Snyder HM, Sevlever GE, Carrillo MC, Caramelli P; LatAm-FINGERS Study Group. Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial. Lancet. 2026 Aug 1;408(10553):417-429. doi: 10.1016/S0140-6736(26)01278-X. Epub 2026 Jul 13.
- Project summary.Link provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Alzheimer Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ricardo Francisco Allegri, MD, Ph.D principal investigator
Fleni Neurological Institute, Buenos Aires, Argentina
Lucía Crivelli, Ph.D principal investigator
Fleni Neurological Institute, Buenos Aires, Argentina
Gustavo Emilio Sevlever, MD, Ph.D principal investigator
Fleni Neurological Institute, Buenos Aires, Argentina
13 sites in 12 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Systematic Lifestyle Intervention and Flexible Lifestyle Intervention in people with Alzheimer Disease, run by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia at 13 sites in 12 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 13 sites in Brazil, Argentina, Bolivia, Chile, Colombia and 7 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reach (time frame: Up to 2 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06492967, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.